TOKYO–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC). Datroway is a specifically engineered TROP2 directed DXd antibo